文献速递神经肿瘤

IDH突变型低级别胶质瘤的体积分析:治疗前后肿瘤生长率的自然史研究

Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
PubMed 文献 · Neuro Oncol · 2020-01-01

这项多中心回顾性研究纳入230例IDH1/2突变型低级别胶质瘤成人患者,用混合效应模型估算治疗前肿瘤体积生长率,并对95例有治疗后影像者分析治疗前后生长率变化。治疗前生长率为27.37%/180天,治疗后生长率较治疗前显著下降。1p/19q共缺失组生长率显著慢于非共缺失组。

要点

  • 230例IDH突变型低级别胶质瘤治疗前体积生长率为27.37%/180天(95%CI 23.36%–31.51%)。
  • 95例治疗前后均有影像者,治疗后生长率较治疗前显著下降(P<0.0001)。
  • 1p/19q共缺失组生长率22.84%显著慢于非共缺失组35.49%(P=0.0108)。

核心结论

  • 本研究评估了IDH突变型胶质瘤标准治疗前后的生长率,尚需进一步研究确认生长率变化是否与患者生存相关及其作为临床试验替代终点的价值。

研究设计与样本

  • 多中心回顾性研究,纳入230例接受手术、放疗或化疗的IDH1/2突变型低级别胶质瘤(世界卫生组织II或III级)成人患者,要求治疗前至少6个月内有3次含T2/FLAIR序列的MRI扫描。

主要发现

  • 全部230例治疗前体积生长率为27.37%/180天(95%CI 23.36%–31.51%)。
  • 95例治疗前后均有影像者,治疗前生长率26.63%/180天(95%CI 19.31%–34.40%),治疗后生长率-15.24%/180天(95%CI -21.37%–-8.62%),差异有统计学意义(P<0.0001)。
  • 1p/19q共缺失组(N=118)生长率22.84%,非共缺失组(N=68)为35.49%,共缺失组显著慢于非共缺失组(P=0.0108)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lower-grade gliomas (LGGs) with isocitrate dehydrogenase 1 and/or 2 (IDH1/2) mutations have long survival times, making evaluation of treatment efficacy difficult. We investigated the volumetric growth rate of IDH mutant gliomas before and after treatment with established glioma therapies to determine whether a significant change in growth rate could be documented and perhaps be used in the future to evaluate treatment response to investigational agents in LGG trials. METHODS: In this multicenter retrospective study, 230 adult patients with IDH1/2 mutated LGGs (World Health Organization grade II or III) undergoing surgery, radiation, or chemotherapy for progressive non-enhancing tumor were identified. Subjects were required to have 3 MRI scans containing T2/fluid attenuated inversion recovery imaging spanning a minimum of 6 months prior to treatment. A mixed-effect model was used to estimate tumor growth prior to treatment. A subset of 95 patients who received chemotherapy, radiotherapy, or chemoradiotherapy and had 2 posttreatment imaging time points available were evaluated for change in pre- and posttreatment volumetric growth rates using a piecewise mixed model. RESULTS: The pretreatment volumetric growth rate across all 230 patients was 27.37%/180 days (95% CI: [23.36%, 31.51%]). In the 95 patients with both pre- and posttreatment scans available, there was a significant difference in volumetric growth rates before (26.63%/180 days, 95% CI: [19.31%, 34.40%]) and after treatment (-15.24% /180 days, 95% CI: [-21.37%, -8.62%]) (P < 0.0001). The growth rates for patient subgroup with 1p/19q codeletion (N = 118) was significantly slower than the rate of the 1p/19q non-codeleted group (N = 68) (22.84% vs 35.49%, P = 0.0108). CONCLUSION: In this study, we evaluated the growth rates of IDH mutant gliomas before and after standard therapy. Further study is needed to establish whether a change in growth rate is associated with patient survival and its use as a surrogate endpoint in clinical trials for IDH mutant LGGs.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Huang RY, Young RJ, Ellingson BM, et al. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro Oncol. 2020. PMID: 32328652. doi:10.1093/neuonc/noaa105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。